4-amino-lh-pyrazol-3(2H)-one derivatives for use in treating skin diseases

Topical metamizole sodium derivatives with a pyrazolone moiety effectively treat and prevent skin diseases by addressing viral and inflammatory symptoms, offering rapid relief across diverse age groups and lesion stages.

WO2026239381A1PCT designated stage Publication Date: 2026-11-19SIELOTECH LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2026/050394
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing treatments for skin diseases, particularly viral and inflammatory skin conditions, are inadequate in providing rapid and effective relief across various age groups and stages of lesion development.

Method used

Topical administration of metamizole sodium or its derivatives, which contain a pyrazolone moiety, to treat or prevent skin diseases by addressing viral and inflammatory symptoms.

Benefits of technology

Provides rapid relief of viral and inflammatory skin symptoms across a broad age range and at different stages of lesion development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000003_0002
    Figure IMGF000003_0002
Patent Text Reader

Abstract

The present disclosure provides small molecule compounds and uses thereof in treating or preventing skin disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] COMPOUNDS AND USES THEREOF

[0002] TECHNOEOGICAE FIELD

[0003] The present disclosure relates to compounds and uses thereof in treating disease.

[0004] BACKGROUND ART

[0005] References considered to be relevant as background to the presently disclosed subject matter are listed below:

[0006] [1] International patent application publication No. WO2014117999

[0007] [2] US patent application publication No. US2019 / 0060220.

[0008] [3] US patent application publication No. US2021 / 0379087.

[0009] [4] US patent application publication No. US2009 / 0312433.

[0010] Acknowledgement of the above references herein is not to be inferred as meaning that these are in any way relevant to the patentability of the presently disclosed subject matter.

[0011] BACKGROUND WO2014117999 discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and / or an inflammatory disease in an individual using such pharmaceutical compositions.

[0012] US 2019 / 0060220 provides compositions and methods for cellular regeneration and more rapid healing of surface lesions such as cuts, abrasions, rashes and other skin disturbances.

[0013] US2021 / 0379087 discloses a composition comprising one or more inhibitors capable of inhibiting at least two of cyclooxygenase- 1 (COX-1), cyclooxygenase-2 (COX-2) and lipoxygenase or a composition comprising one or more inhibitors capable of inhibiting an enzyme with arachidonate-Co A ligase activity.US2009 / 0312433 discloses a method of reducing a VR1 -antagonist-induced increase in body temperature in a mammal in need thereof, comprising the step of administering an antipyretic agent to the mammal and the like.

[0014] GENERAL DESCRIPTION

[0015] The present disclosure provides in accordance with some aspects, a small molecule compound (SMC) for use in a method of treating or preventing a skin disease, wherein the SMC has the general Formula (I):

[0016]

[0017] or a pharmaceutically acceptable salt, solvate, hydrate, any stereoisomer thereof or a physiologically functional derivative thereof,

[0018] wherein each of Ri, R2, R3, R4, and R5, is independently hydrogen, cyano, amino, amide, nitro, hydroxy, oxo, halo, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl, C2-C12 haloalkenyl, C2-Ci2alkynyl, C2-C12 haloalkynyl, C1-C12 alkoxy, C1-C12 haloalkoxy, urea, sulfonylurea, sulfonamidyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, trifluoromethyl, -N(R6)(R7), C(=O), -C(=O)R6, -CH2R6, -CO2R6, -C(O)N(R6)(R7), -SO2N(R6)(R7), -SOR6, -SO2(R6), or Li- R8, each optionally substituted with C1-C12 alkyl, C1-C12 haloalkyl, or halo;

[0019] Li is -(CH2)m-,-C(O)-, -O-, -NH-, -O-CH2-, -N-(CH2)m-, -NH-C(O)- , m is selected from 0, 1, 2, 3, 4, 5 or 6,

[0020] R8is hydrogen, cyano, amino, amide, nitro, hydroxy, oxo, halo, C1-C12 alkyl, Ci-C12 haloalkyl, C2-C12 alkenyl, C2-C12 haloalkenyl, C2-C12 alkynyl, C2-C12 haloalkynyl, Ci-C 12 alkoxy, C1-C12 haloalkoxy, urea, sulfonylurea, sulfonamidyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, trifluoromethyl, -N(Rn)(R12), -C(O)Rn, -CH2R11, -CO2R6, -C(O)N(R6)(R7), -SO2N(R6)(R7), -SO2(R6),each R6and R7is independently H, hydroxyl, C1-C12 alkyl, C1-C12 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl.

[0021] In accordance with some further aspects, the present disclosure provides an SMC having the chemical structure of Formula (X):

[0022]

[0023] ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid or a pharmaceutically acceptable salt, solvate, hydrate, any stereoisomer thereof or a physiologically functional derivative thereof for use in a method of treating or preventing a skin disease.

[0024] In accordance with some other aspects, the present disclosure provides an SMC having the chemical structure of Formula (X):

[0025]

[0026] or a sodium salt of thereof for use in a method of treating or preventing a skin disease.

[0027] In accordance with some further aspects, the present disclosure provides an SMC having the chemical structure of Formula (X):

[0028]

[0029] ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid or a pharmaceutically acceptable salt, solvate, hydrate, any stereoisomer thereof or a physiologically functional derivative thereof for use in a method of treating or preventing a viral infection.

[0030] In accordance with some other aspects, the present disclosure provides an SMC having the chemical structure of Formula (X):

[0031]

[0032] or a sodium salt of thereof for use in a method of treating or preventing a viral infection.

[0033] In accordance with some other aspects, the present disclosure provides a pharmaceutical composition comprising at least one SMC as described herein.

[0034] In accordance with some other aspects, the present disclosure provides a method for treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject in need thereof, the method comprises administering to the subject a therapeutically effective amount of at least one SMC as described herein.

[0035] In accordance with some other aspects, the present disclosure provides a method for treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a viral infection in a subject in need thereof, the method comprises administering to the subject a therapeutically effective amount of at least one SMC as described herein.In accordance with some other aspects, it is provided use of at least one SMC as described herein in the preparation of a composition.

[0036] DETAILED DESCRIPTION OF EMBODIMENTS

[0037] The present disclosure is based on the findings that metamizole also known as dipyrone can effectively treat skin disease, including, inter alia, skin infection disease.

[0038] As shown in the Examples below, topical administration of metamizole sodium provided rapid relief of viral and inflammatory skin symptoms across a broad age range and at different stages of lesion development. Based on these findings, it was suggested that metamizole or derivatives thereof may be used for treating or preventing multiple skin diseases, specifically viral skin disease.

[0039] Accordingly, the present disclosure provides a small molecule compound (SMC) that comprises a pyrazolone moiety for use in a method of treating or preventing a skin disease.

[0040] The term “pyrazolone moiety,” as used herein, refers to a SMC comprising a pyrazolone scaffold that is further substituted at various positions providing a wide range of chemical diversity and potential therapeutic effects.

[0041] In the following text, when referring to at least one SMC it is to be understood as also referring to the compositions, methods, and uses disclosed herein. Thus, whenever providing a feature with reference to the at least one SMC, it is to be understood as defining the same feature with respect to the compositions, methods, and uses, mutatis mutandis.

[0042] As used herein, the expression “pyrazolone moiety” denotes a five-membered heteroaromatic scaffold. In some embodiments, the pyrazolone moiety has a core structure of Formula (I) below, in which positions 1-5 are numbered clockwise from the N-l atom and Rl-R5are optional substituents as defined herein.

[0043] Unless otherwise indicated, every reference to a pyrazolone-containing small-molecule compound (SMC) in this disclosure is a reference to a compound that conforms to Formula (I), including any pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or physiologically functional derivative thereof.In accordance with some aspects, the present disclosure provides at least one SMC for use in a method of treating or preventing a skin disease, wherein the SMC has the general Formula (I):

[0044]

[0045] or a pharmaceutically acceptable salt, solvate, hydrate, any stereoisomer thereof or a physiologically functional derivative thereof,

[0046] wherein each of Ri, R2, R3, R4, and R5, is independently hydrogen, cyano, amino, amide, nitro, hydroxy, oxo, halo, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl, C2-C12 haloalkenyl, C2-Ci2alkynyl, C2-C12 haloalkynyl, C1-C12 alkoxy, C1-C12 haloalkoxy, urea, sulfonylurea, sulfonamidyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, trifluoromethyl, -N(R6)(R7), C(=O), -C(=O)R6, -CH2R6, -CO2R6, -C(O)N(R6)(R7), -SO2N(R6)(R7), -SOR6, -SO2(R6), or Li- R8, each optionally substituted with C1-C12 alkyl, C1-C12 haloalkyl, or halo;

[0047] Li is -(CH2)m-,-C(O)-, -O-, -NH-, -O-CH2-, -N-(CH2)m-, -NH-C(O)- , m is selected from 0, 1, 2, 3, 4, 5 or 6,

[0048] R8is hydrogen, cyano, amino, amide, nitro, hydroxy, oxo, halo, C1-C12 alkyl, Ci-C12 haloalkyl, C2-C12 alkenyl, C2-C12 haloalkenyl, C2-Ci2alkynyl, C2-C12 haloalkynyl, Ci-C12 alkoxy, C1-C12 haloalkoxy, urea, sulfonylurea, sulfonamidyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, trifluoromethyl, -N(Rn)(R12), -C(O)Rn, -CH2R11, -CO2R6, -C(O)N(R6)(R7), -SO2N(R6)(R7), -SO2(R6),

[0049] each R6and R7is independently H, hydroxyl, C1-C12 alkyl, C1-C12 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl.

[0050] In some embodiments, in the SMC of Formula (I), each of Ri, R2, R3, R4, and R5, is independently hydrogen, C1-C12 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C(=O), -C(=O)R6, -SOR6, -SO2(R6), or Li- R8, each optionally substituted with C1-C12 alkyl, C1-C12 haloalkyl, or halo; Li is -(CFDm, m is selected from 0, 1, 2, 3, 4, 5 or 6, R8is C1-C12 alkyl, -St CR6), R6is hydroxyl, C1-C12 alkyl, C1-C12 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl.

[0051] In some embodiments, in the SMC of Formula (I) each of Ri, R2, R3, R4, and R5, is independently Ci-alkyl, aryl, heteroaryl, C(=O), -C(=O)R6, or Li- R8, Li is -(CH2)-, R8is -SO2(R6), R6is hydroxyl or C1-C12 alkyl.

[0052] In some embodiments, in the SMC of Formula (I) each of Ri, R2, R3, R4, and R5, is independently Ci-alkyl, aryl, heteroaryl, or Li- R8, Li is -(CH2)-, R8is -SO2(R6), R6is hydroxyl.

[0053] In some embodiments, in the SMC of Formula (I) Ri is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, R2 is hydrogen or C1-C12 alkyl, R3 is hydrogen or Ci-C 12 alkyl, R4 is hydrogen or C1-C12 alkyl, R5 is hydrogen, C1-C12 alkyl, or Li- R8, Li is -(CH2)m-, m is selected from 1, 2, 3, R8is hydrogen, -SO2(R6), R6is hydroxyl.

[0054] In some embodiments, in the SMC of Formula (I) Ri is aryl, R2 is Ci alkyl, R3 is Ci alkyl, R4is Ci alkyl, R5is -(CH2)-SO2(OH).

[0055] In some embodiments, in the SMC of Formula (I) Ri is aryl, R2 is Ci alkyl, R3 is Ci alkyl, R4 is Ci alkyl, R5 is hydrogen.

[0056] In some embodiments, in the SMC of Formula (I) Ri is aryl, R2 is Ci alkyl, R3 is Ci alkyl, R4 is hydrogen, R5 is hydrogen.

[0057] In some embodiments, in the SMC of Formula (I) Ri is aryl.

[0058] In some embodiments, the SMC of Formula (I) has the general Formula (II). In some embodiments, the SMC has the general Formula (II):

[0059]

[0060] In some embodiments, in the SMC of Formula (I) and / or the SMC of Formula (II), each of R2 and R3 is independently hydrogen, C1-C12 alkyl.In some embodiments, in the SMC of Formula (I) and / or the SMC of Formula (II), each of R2 and R3 is independently hydrogen, Ci-alkyl.

[0061] In some embodiments, the SMC of Formula (I) has the general Formula (III). In some embodiments, the SMC of Formula (II) has the general Formula (III). In some embodiments, the SMC has the general Formula (III):

[0062]

[0063] In some embodiments, in the SMC of Formula (I) and / or the SMC of Formula (II) and / or the SMC of Formula (III), each of R4 or R5 is independently hydrogen, C1-C12 alkyl.

[0064] In some embodiments, in the SMC of Formula (I) and / or the SMC of Formula (II) and / or SMC of Formula (III), each of R4 or R5 is independently hydrogen or Ci-alkyl.

[0065] In some embodiments, the SMC of Formula (I) has the general Formula (IVa). In some embodiments, the SMC is 4-amino-l,5-dimethyl-2-phenyl-l,2-dihydro-3H-pyrazol-3 -one.

[0066] In some embodiments, the SMC is 4-amino-l,5-dimethyl-2-phenyl-l,2-dihydro-3H-pyrazol-3-one having the chemical structure of Formula (IVa):

[0067]

[0068] In some embodiments, the SMC of Formula (I) is an amino-phenazone.

[0069] In some embodiments, the SMC is 4-(dimethylamino)-l,5-dimethyl-2-phenyl-l,2-dihydro-3H-pyrazol-3-one.In some embodiments, the SMC of Formula (I) has the general Formula (IVb). In some embodiments, the SMC is 4-(dimethylamino)-l,5-dimethyl-2-phenyl-l,2-dihydro-3H-pyrazol-3-one having the chemical structure of Formula (IVb):

[0070]

[0071] In some embodiments, the SMC of Formula (I) has the general Formula (IVc). In some embodiments, the SMC is l,5-dimethyl-4-(methylamino)-2-phenylpyrazol-3-one having the chemical structure of Formula (IVc):

[0072]

[0073] In some embodiments, the SMC of Formula (IVc) is denoted at times as Noramidopyrine.

[0074] In some embodiments, the SMC of Formula (I) has the general Formula (IVd). In some embodiments, the SMC is N-(l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)formamide.

[0075] In some embodiments, the SMC is N-(l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)formamide having the chemical structure of Formula (IVd):

[0076]

[0077] In some embodiments, the SMC of Formula (I) has the general Formula (IVe). In some embodiments, the SMC is N-(2,3-Dimethyl-5-oxo-l-phenyl-3-pyrazolin-4-yl)acetamide.

[0078] In some embodiments, the SMC is N-(2,3-Dimethyl-5-oxo-l-phenyl-3-pyrazolin-4-yl)acetamide having the chemical structure of Formula (IVe):

[0079]

[0080] In some embodiments, in the SMC of Formula (I) and / or the SMC of Formula (II) and / or the SMC of Formula (III), R4 is Li- R8, Li is -(CFDm-, m is selected from 1, 2, 3, R8is hydrogen, -SO2N(R6)(R7), -SO2(R6).

[0081] In some embodiments, in the SMC of Formula (I) and / or the SMC of Formula (II) and / or the SMC of Formula (III), R4 is Li- R8, Li is -(CH2)-, R8is -SO2(R6) and R6is hydroxyl.

[0082] In some embodiments, the SMC has the general Formula (V):

[0083] O

[0084]

[0085] O (V).In some embodiments, the SMC of Formula (I) or Formula (V) has the general Formula (VI).

[0086] In some embodiments, the SMC has the general Formula (VI):

[0087]

[0088] O (VI).

[0089] In some embodiments, the SMC of Formula (I) or Formula (V) has the general Formula (VII).

[0090] In some embodiments, the SMC has the general Formula (VII):

[0091]

[0092] In some embodiments, in the SMC of Formula (VII), R2 is hydrogen or C1-C12 alkyl, R3 is hydrogen or C1-C12 alkyl, R5 is hydrogen, C1-C12 alkyl.

[0093] In some embodiments, in the SMC of Formula (VII), R2 is Ci alkyl, R3 is Ci alkyl, R5 is Ci alkyl.

[0094] In some further embodiments, the SMC for use in the present disclosure is ((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid.

[0095] In some further embodiments, the SMC for use in the present disclosure is ((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X):

[0096]

[0097] or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or physiologically functional derivative thereof. It should be appreciated that in some embodiments the disclosed SMC of the present disclosure may be any derivative or related compound to the compound of Formula (X).

[0098] SMC 1 of the present disclosure is known as metamizole.

[0099] In some embodiments, the SMC is in the form of a pharmaceutically acceptable salt. The present disclosure is not limited to a specific pharmaceutically acceptable salt and the SMC of the present disclosure may be in the form of multiple salts.

[0100] When referring to a salt, it should be understood that the molar ratio between the counter-ion(s) and SMC 1 is selected to achieve charge neutrality and may therefore vary with the valency of the ion. In some embodiments, the ratio may be ~1:1. In some examples, the ratio is 1:1 when the counter-ion is monovalent (e.g., Na+, K+). In some embodiments, the ratio may be -0.5:1.+). In some embodiments, the ratio may be -0.5:1 when the counter-ion is divalent (e.g., Ca2+, Mg2+).

[0101] In some embodiments, the SMC is in the form of a pharmaceutically acceptable salt selected from the group consisting of a sodium salt, a calcium salt, a potassium salt, a magnesium salt, and any combination thereof.

[0102] In some embodiments, SMC 1 is in the form of a pharmaceutically acceptable salt selected from the group consisting of a sodium salt, a calcium salt, a potassium salt, a magnesium salt, and any combination thereof.

[0103] In some embodiments, the SMC is in the form of sodium salt SMC. In some embodiments, the SMC is a sodium salt of SMC 1. In some embodiments, the SMC is sodium; [(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonate.In some embodiments, the SMC is in the form of magnesium salt SMC. In some embodiments, the SMC is a magnesium salt of SMC 1. In some embodiments, the SMC is magnesium; [(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)methylamino]methanesulfonate.

[0104] In some embodiments, the SMC is in the form of calcium salt SMC. In some embodiments, the SMC is a calcium salt of SMC 1. In some embodiments, the SMC is calcium; [(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)methylamino]methanesulfonate.

[0105] In some embodiments, the disclosed SMC is used for treating at least one skin disease.

[0106] A further aspect of the present disclosure relates to a SMC having the chemical structure of Formula (X) ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or physiologically functional derivative thereof, for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of at least one skin disease, in a subject.

[0107] A further aspect of the present disclosure relates to an SMC being sodium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonate solvate, hydrate, stereoisomer or physiologically functional derivative thereof, for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of at least one skin disease, in a subject.

[0108] A further aspect of the present disclosure relates to an SMC being calcium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonate solvate, hydrate, stereoisomer or physiologically functional derivative thereof, for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of at least one skin disease, in a subject.

[0109] A further aspect of the present disclosure relates to an SMC being magnesium salt;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonate solvate, hydrate, stereoisomer or physiologically functional derivative thereof, for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of at least one skin disease, in a subject.As used herein, a skin disease denotes any disease, disorder, or condition that affects the skin (cutaneous tissue), including the integumentary system of a subject. The term skin disease as used herein encompasses the primary dermatologic disorder and any secondary or associated conditions, manifestations or comorbidities arising therefrom (e.g., psoriatic arthritis, microbial super-infection, systemic inflammation).

[0110] For the purposes of the present disclosure, the term may also encompass conditions affecting mucous membranes (e.g., oral or nasal mucosa) that are pathophysiologically similar to cutaneous lesions or responsive to the same therapeutic interventions (e.g., herpes labialis involving the oral mucosa).

[0111] As appreciated, the skin is the soft, flexible outer tissue covering the body of a vertebrate animal, with three primary functions: protection, regulation, and sensation. Mammalian skin is composed of three main layers: the epidermis, the dermis, and the hypodermis. The epidermis forms the outermost protective barrier, helping to retain moisture and prevent pathogen entry. It comprises a basal proliferative layer, a suprabasal and spinous layer, a granular layer of terminally differentiated keratinocytes, and a stratified squamous epithelium. Most of the epidermis (approximately 95%) is composed of keratinocytes.

[0112] For the purposes of this disclosure, the term skin also includes epithelial surfaces contiguous with the skin, such as the external auditory canal, where similar pathological features and responses to topical treatment may occur.

[0113] A skin disease in accordance with the present disclosure may be characterized by one or more skin irregularities. Skin irregularities may include at least one symptom selected from: raised bumps, a rash, acne, itchiness, scaly or rough skin, peeling skin, blisters, ulcers, open sores or lesions, dry or cracked skin, discolored patches of skin, fleshy bumps, warts or other skin growths, changes in mole color or size, loss of skin pigment, inflammation, excessive flushing, or pain, tingling, or burning sensations of the skin.

[0114] In some examples, the skin disease is acne. In some examples, the skin disease is rash. In some examples, the skin disease is acne-like rash.

[0115] As used herein, skin irregularities may also include prodromal symptoms such as tingling, pain, or burning, which may precede visible lesions — particularly in the contextof recurrent viral skin infections such as herpes. In some embodiments, the skin disease may present without visible lesions, and may be diagnosed or treated based on such characteristic prodromal symptoms.

[0116] The present disclosure is not limited to a specific skin disease and is applicable to a variety of cutaneous disorders. The term skin disease encompasses both inherent (genetic) and acquired conditions. In some embodiments, the skin disease is a chronic disease.

[0117] It should be noted that when referring to a skin disease it encompasses any conditions associated with the skin disease.

[0118] In some embodiments, the skin disorder is one or more of the following: a keratoderma, an ichthyosis, epidermolysis bullosa, pachyonychia congenita, pruritus (itch), dry skin (Xerosis), eczema (including atopic dermatitis) or burns.

[0119] In some embodiments, the skin disorder is pruritus.

[0120] In some embodiments, the skin disease is a skin infection disease, an inflammatory skin disease, an autoimmune skin disease or any combination thereof.

[0121] In some embodiments, the skin disease is a skin infection disease.

[0122] As used herein, a skin infection disease refers to an infectious condition that primarily affects the skin and / or related integumentary structures. Such conditions may involve the skin surface, hair follicles, glands, or deeper layers, and may also spread from or to other tissues or organs while manifesting with cutaneous symptoms. The skin infection may affect multiple areas of the body, be localized to specific regions, or be widespread.

[0123] In some examples, the skin infection disease may be localized to the skin surface, hair follicles, glands, or alternatively deeper layers of the skin, or they may spread to or from other tissues or organs while manifesting with cutaneous symptoms.

[0124] The skin infection may be caused by one or more microbial agents. In some embodiments, it is caused by bacteria, viruses, fungi, parasites, or any combination thereof. Mixed infections involving two or more types of microbial agents are also encompassed. The infection may be acute, chronic, or recurrent.

[0125] In some embodiments, the skin infection disease is caused by one or more viruses.In some embodiments, the skin infection disease is a viral infection.

[0126] As used herein, the phrase ‘viruses causing skin disease’ or "viral infection" or "viral skin disease" encompasses those viruses that characteristically present with cutaneous manifestations, including but not limited to papovaviruses (e.g., HPV), herpesviruses (e.g., herpes simplex, varicella-zoster), poxviruses (e.g., smallpox, vaccinia, molluscum contagiosum), rubella virus, measles virus, and arboviruses that produce rashes (e.g., dengue, Zika) and may also viruses which, although primarily systemic, may cause or be associated with significant skin lesions, such as HIV, HTLV, and certain herpesviruses like Epstein-Barr and cytomegalovirus.”

[0127] In some embodiments, the viral infection is caused by a herpes virus. In some embodiments, the viral infection caused by a herpes virus is associated with orofacial and facial skin lesions.

[0128] In some embodiments, the viral infection caused by a herpes virus is associated with orofacial and facial skin blisters.

[0129] In some embodiments, the viral infection caused by a herpes virus is associated with orofacial and facial skin ulcers.

[0130] As used herein, the term “herpes virus” refers to any member of the Herpesviridae family of enveloped, double- stranded DNA viruses, which are characterized by their ability to establish lifelong latency in the host, with the potential for reactivation under various conditions (e.g., stress, immunosuppression).

[0131] In some embodiments, the herpes virus is selected from the group consisting of Herpes Simplex Virus (HSV) and / or Human Herpesvirus (HHV).

[0132] In some embodiments, the HSV is Herpes Simplex Virus Type 1 (HSV-1) and / or Herpes Simplex Virus Type 2 (HSV-2).

[0133] In some embodiments, the HHV is one or more of Varicella-Zoster Virus (VZV, or HHV-3), Epstein-Barr Virus (EBV, HHV-4), Cytomegalovirus (CMV, HHV-5), Human Herpesvirus 6 (HHV-6), Human Herpesvirus 7 (HHV-7), Human Herpesvirus 8 (HHV-8) or any combination thereof.

[0134] In some embodiments, the herpes virus is one or more of HSV-1, HSV-2, HHV-3, HHV-4, HHV-5, HHV-6, HHV-7, HHV-8 or any combination thereof.In some embodiments, the viral infection is caused by Herpes Simplex Virus (HSV).

[0135] In some embodiments, the viral infection is caused by HSV-1.

[0136] In some embodiments, the viral infection caused by HSV-1 is associated with orofacial and facial skin lesions.

[0137] In some embodiments, the viral infection caused by HSV-1 is selected from the group consisting of herpes labialis (cold sores), primary herpetic gingivostomatitis, herpetic whitlow, herpes gladiatorum, and eczema herpeticum.

[0138] In some embodiments, the viral infection is herpes labialis.

[0139] In some embodiments, the viral infection is caused by (VZV, or HHV-3).

[0140] In some embodiments, the viral infection is chickenpox (varicella).

[0141] In some embodiments, the viral infection is shingles (herpes zoster).

[0142] In some embodiments, the skin infection disease is a skin fungal infection.

[0143] As used herein, the term “ skin fungal infection” refers to any infection affecting the skin, hair, or nails that is caused by pathogenic fungi, including dermatophytes, yeasts, and molds.

[0144] In some embodiments, the skin fungal infection is one or more of dermatophytosis, pityriasis versicolor (tinea versicolor), cutaneous candidiasis and subcutaneous mycosis.

[0145] In some embodiments, dermatophytosis is one or more of tinea capitis (scalp), tinea corporis (body), tinea cruris (groin / jock itch), tinea pedis (athlete’s foot), tinea unguium (onychomycosis; nails).

[0146] In some embodiments, cutaneous candidiasis is one or more of intertrigo (skin folds), diaper candidiasis, chronic mucocutaneous candidiasis.

[0147] In some embodiments, the subcutaneous mycosis is one or more of sporotrichosis, chromoblastomycosis, mycetoma, phaeohyphomycosis.

[0148] In some embodiments, the skin infection disease is a parasitic skin disease.

[0149] In some embodiments, the parasitic skin disease is ectoparasitic infection and endoparasitic infection with cutaneous manifestations.In some embodiments, the ectoparasitic infection is selected from the list of one or more of scabies, pediculosis, mite-related dermatosis.

[0150] In some embodiments, the skin disease is an inflammatory skin disease.

[0151] As used herein, the term “inflammatory skin disease” refers to a disease, condition, or disorder in which inflammation characterized by one or more of redness, swelling, heat, pain, or dysfunction plays a principal or significant role in its pathophysiology. The term inflammatory skin disease encompasses any disease in which inflammatory processes may involve immune-mediated mechanisms, dysregulated cytokine signaling, or both acute and chronic inflammatory responses.

[0152] The term inflammatory skin disease encompasses both acute and chronic inflammatory disorders of the skin, as well as localized or widespread manifestations.

[0153] The skin inflammatory disease may be present in multiples skin areas.

[0154] In some examples, the skin inflammatory disease may be localized to specific body regions or may be widespread nearly the entire body.

[0155] In some examples, the skin inflammatory disease may be localized in the scalp, face, flexural areas (skin folds), hands, feet, trunk, torso, nails, or may be widespread.

[0156] In some embodiments, the skin inflammatory disease is one or more of eczema (atopic dermatitis), contact dermatitis, seborrheic dermatitis, psoriasis, rosacea, lichen planus, autoimmune blistering diseases (e.g., pemphigus, bullous pemphigoid).

[0157] In some embodiments, the eczema is foot eczema or foot dermatitis.

[0158] In some embodiments, the atopic dermatitis is chronic itching in the ear canal. In some embodiments, the skin disease is an autoimmune skin disease.

[0159] As used herein autoimmune skin diseases arise from an inappropriate immune response against self-antigens or host tissues. This may be restricted to certain organs (e.g. in autoimmune thyroiditis) or involve a particular tissue in different places (e.g. Goodpasture's disease which may affect the basement membrane in both the lung and the kidney).

[0160] According to some embodiments, the autoimmune disease is associated with changes in the skin.In some embodiments, the autoimmune skin disorder is at least one of behcet's disease, dermatitis herpetiformis, atopic dermatitis, dermatomyositis, lichen planus, linear IgA disease, lupus of the skin, scleroderma, vitiligo, pyoderma gangrenosum, pemphigoid, pemphigus, vasculitis or psoriasis.

[0161] In a further aspect, the present disclosure provides a pharmaceutical composition comprising an effective amount of at least one SMC having the general formulae (I), (II), (III), (V), (VI), (VII) or a pharmaceutically acceptable salt or hydrate thereof including any stereoisomer thereof, or any vehicle, matrix, nano- or micro-particle comprising the same for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject.

[0162] In some embodiments, the composition of the invention may optionally further comprise at least one of pharmaceutically acceptable carrier / s, excipient / s, additive / s diluent / s and adjuvant / s. As used herein “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic composition is contemplated.

[0163] In some other embodiments, the pharmaceutical composition may comprise a vehicle, matrix, nano- or micro-particle.

[0164] In a further aspect, the present disclosure provides a pharmaceutical composition comprising an effective amount of at least one SMC having the general formulae (IVa), (IVb), (IVc), (IVd), (IVe) or a pharmaceutically acceptable salt or hydrate thereof including any stereoisomer thereof, or any vehicle, matrix, nano- or micro-particle comprising the same for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject.

[0165] In a further aspect, the present disclosure provides a pharmaceutical composition comprising an effective amount of an SMC being ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X) ("SMC 1") or a pharmaceutically acceptable salt or hydrate thereof for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject.In some embodiments, the pharmaceutical composition is for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin infection disease, an inflammatory skin disease, an autoimmune skin disease or any combination thereof in a subject.

[0166] In a further aspect, the present disclosure provides a pharmaceutical composition comprising an effective amount of an SMC being ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X) ("SMC 1 ") for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin infection disease, an inflammatory skin disease, an autoimmune skin disease or any combination thereof in a subject.

[0167] In a further aspect, the present disclosure provides a pharmaceutical composition comprising an effective amount of a SMC being ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X) ("SMC 1 ") for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin infection disease in a subject.

[0168] In a further aspect, the present disclosure provides a pharmaceutical composition comprising an effective amount of a SMC being ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X) ("SMC 1") for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin infection disease in a subject, wherein the skin infection disease is caused by a herpes virus.

[0169] In a further aspect, the present disclosure provides a pharmaceutical composition comprising an effective amount of a SMC being ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X) ("SMC 1") for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of herpes labialis in a subject.

[0170] In some aspects, the disclosure provides a pharmaceutical composition comprising an effective amount of sodium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino] methanesulfonate for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject.

[0171] In some embodiments, sodium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino] methanesulfonate is for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin infection disease.

[0172] In some aspects, the disclosure provides a pharmaceutical composition comprising an effective amount of calcium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino] methanesulfonate for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject.

[0173] In some embodiments, calcium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino] methanesulfonate is for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin infection disease.

[0174] In some aspects, the disclosure provides a pharmaceutical composition comprising an effective amount of magnesium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino] methanesulfonate for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject.

[0175] In some embodiments, magnesium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino] methanesulfonate is for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin infection disease.

[0176] The pharmaceutical composition of the invention can be administered and dosed by the methods of the invention, in accordance with good medical practice. Hence, the pharmaceutical compositions or SMC described herein may be adjusted, adapted or configured for administration by a variety of administration routes.

[0177] For example, the compositions used in the methods of the invention, described herein below, may be adapted for administration by various modes of administration known in the art including, for example, systemic, parenteral, intraperitoneal, transdermal, oral (including buccal or sublingual), rectal, topical (including buccal or sublingual), vaginal, intranasal and any other appropriate routes. Specific examples include but not limited to, injection (e.g., using a subcutaneous, intramuscular, intravenous, or intradermal injection), intranasal administration and oral administration.In some embodiments, administration of the SMCs of the invention or compositions comprising the SMCs is by systemic administration. Hence the SMCs described herein or the compositions comprising the SMCs is adjusted to be suitable for systemic administration. "Systemic administration" and “ administered systemically” as used herein mean that the administration of a compound or a composition comprising at least one compound of the invention into the circulatory system so that the entire body is affected.

[0178] In accordance with some embodiments, the SMCs described herein or the compositions comprising the SMCs of the invention are suitable for systemic administration.

[0179] In some embodiments, the SMCs described herein or the compositions comprising the SMCs is administered enterally.

[0180] In some embodiments, the SMCs described herein or the compositions comprising the SMCs is administered orally.

[0181] Compositions for oral administration may include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films, ovules, sprays or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. In some embodiments, the composition is in a liquid form.

[0182] It should be understood that in addition to the ingredients particularly mentioned above, the compositions may also include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

[0183] In some embodiments, the SMCs or the compositions comprising the SMCs is administered parentally.

[0184] "Parenteral administration" and "administered parenterally" as used herein includes modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.In some embodiments, the SMCs described herein or the compositions comprising the SMCs is suitable for intravenous injection. In some embodiments, the SMCs described herein or the compositions comprising the SMCs is suitable for intravenous infusion.

[0185] In some embodiments, administration of the SMCs described herein or the compositions comprising the SMCs of the invention is by local administration.

[0186] In some embodiments, the SMCs described herein or the compositions comprising the SMCs is administered topically. Hence the SMCs described herein or the compositions comprising the SMCs is adjusted to be suitable for topical administration. "Topical administration", “administered topically” and “topical application” as used herein mean that the administration or application of SMCs described herein or the compositions comprising the SMCs is applied to a particular place on or in the body. Typically, topical administration refers to application to body surfaces such as skin or mucous membranes.

[0187] The topically administrable SMCs described herein or the compositions comprising the SMCs may be formulated into a suitable formulation or composition. In some examples, the composition is suitable for topical administration.

[0188] These topical vehicles may be optimized for viscosity, penetration, release rate, and patient compliance, depending on the SMC and therapeutic target.

[0189] The carriers may be selected from powders, oils, creams, foams, ointments, lotions, gels, pastes, mousses, hydrogels or delivery systems such as liposome, niosome, microsponge, microemulsion, microsphere, SLN, aerosol and others.

[0190] The SMCs described herein or the compositions comprising the SMCs may be effectively dispersed or suspended or solubilized in a liquid medium to form a solution, a suspension or a dispersion that may be applied topically, sprayed onto the skin or delivered by contact via the use of a sponge, a plaster, a pad or any skin dressing. For some applications, controlled release of the compounds of such delivery systems may be essential.

[0191] In accordance with some embodiments, the SMCs described herein or the compositions comprising the SMCs are suitable for topical administration.

[0192] In some embodiments, the SMCs are suitable for topical administration.In some embodiments, at least one SMC having the general formulae (I), (II), (III), (V), (VI), (VII) or a pharmaceutically acceptable salt or hydrate thereof including any stereoisomer thereof, or any vehicle, matrix, nano- or micro-particle comprising the same is suitable for topical administration.

[0193] In some embodiments, at least one SMC being ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X) ("SMC 1") or a composition comprising SMC 1 is suitable for topical administration.

[0194] In some embodiments, the at least one SMC described herein or a composition comprising the SMC may be formulated into one or more of cream, gel, ointment, lotion, paste, spray, aerosol, transdermal patch, form, solution, suspension, powder, film, film forming solution or any combination thereof.

[0195] In some embodiments, the at least one SMC described herein or a composition comprising the SMC may be formulated as a liquid solution, gel, cream, ointment, spray, or lotion.

[0196] In some embodiments, the at least one SMC described herein or a composition comprising the SMC may be administered to a subject by one or more of the formulations cream, gel, ointment, lotion, paste, spray, aerosol, transdermal patch, form, solution, suspension, powder, film, film forming solution or any combination thereof.

[0197] In some embodiments, the unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.

[0198] As shown in the Examples below, the SMC in a composition successfully treated occurrence of herpes labialis.

[0199] In some embodiments, the SMC is for use in a method of treating herpes labialis at the prodromal stage.

[0200] In some embodiments, the SMC is for use in a method of treating herpes labialis at the blister stage.

[0201] In some embodiments, the SMC is for use in a method of treating herpes labialis at the ulcerative stage.In some embodiments, the SMC is for use in a method of treating herpes labialis at the blister stage with secondary bacterial infection.

[0202] As shown in the Examples below, the SMC is for use in a method of treating occurrence of rash and acne.

[0203] As shown in Example 3 below, the SMC is for use in a method of treating occurrence of chronic itching in the ear canal.

[0204] In a further aspect, the present disclosure provides a method for treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of at least one SMC having the general formulae (I), (II), (III), (V), (VI), (VII) or a pharmaceutically acceptable salt or hydrate thereof including any stereoisomer thereof, or any vehicle, matrix, nano- or micro-particle comprising the same.

[0205] In some embodiments, the method comprises administering to the subject a therapeutically effective amount of at least one SMC represented by at least one of Formula (IVa), (IVb), (IVc), (IVd), (IVe) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or physiologically functional derivative thereof or any combinations thereof.

[0206] In some embodiments, the method comprises administering to the subject a therapeutically effective amount of at least one SMC represented by Formula (X) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or physiologically functional derivative thereof or any combinations thereof.

[0207] In some embodiments, the method comprises topical administration to the subject the SMC being ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or physiologically functional derivative thereof.

[0208] The methods of the invention are applicable to a subject suffering from, suspected of suffering from, or at risk of developing a skin infection disease, an inflammatory skin disease, an autoimmune skin disease or any combination thereof or exhibiting one or more symptoms associated therewith.In some embodiments, the subject is suffering from or suspected of suffering from a skin infection disease or exhibiting one or more symptoms associated therewith.

[0209] In some embodiments, the subject is suffering from or suspected of suffering from a viral infection or exhibiting one or more symptoms associated therewith.

[0210] In some embodiments, the method is applicable for a skin infection disease, an inflammatory skin disease, an autoimmune skin disease or any combination thereof.

[0211] In a further aspect, the present disclosure provides a method for treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject in need thereof, the method comprises administering to the subject a therapeutically effective amount of an SMC being ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X) (denoted herein SMC 1) or a pharmaceutically acceptable salt or hydrate thereof including any stereoisomer thereof, or any vehicle, matrix, nano- or micro-particle comprising the same.

[0212] The at least one SMC, a composition comprising the at least one SMC, or a method of using the same is suitable for patients within a broad age range.

[0213] In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for pediatric patients. In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for patients between about 10 years old and about 13 years old.

[0214] In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for adolescent patients. In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for patients between about 13 years old and about 20 years old.

[0215] In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for young adult patients. In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for patients between about 20 years old and about 30 years old.

[0216] In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for adult patients. In some embodiments, the at leastone SMC, a composition comprising the at least one SMC, or the method is suitable for patients between about 30 years old and about 60 years old.

[0217] In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for elderly patients. In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for patients between about 60 years old and about 80 years old.

[0218] In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for advanced age patients. In some embodiments, the at least one SMC, a composition comprising the at least one SMC, or the method is suitable for patients between about 80 years old and about 100 years old.

[0219] In some embodiments, the patient is male or female.

[0220] In some embodiments, the patient is a non-pregnant female.

[0221] In some embodiments, the patient is a pregnant female.

[0222] In some embodiments, the method comprises topical administration of metamizole to the affected area at amount of at least about 0.1 mg, at times at least about 0.5 mg, at times at least about 1 mg, at times at least about 5 mg, at times at least about 15 mg, at times at least about 25 mg, at times at least about 45 mg, at times at least about 65 mg, at times at least about 100 mg, at times at least about 150 mg, at times at least about 200 mg, at times at least about 250 mg, at times at least about 300 mg, at times at least about 350 mg, at times at least about 400 mg, at times at least about 450 mg, at times at least about 500 mg, at times at least 1000 mg.

[0223] In some embodiments, the method comprises topical administration of metamizole to the affected area at amount of between about 0.1 mg and about 1000 mg, at times between about 10 mg and about 500 mg, at times between about 25 mg and about 250 mg, at times between about 25 mg and about 150 mg, at times between about 25 mg and about 100 mg, at times between about 25 mg and about 50 mg.

[0224] In some embodiments, the method comprises topical administration of metamizole to the affected area at amount of about 1 mg, at times about 5 mg, at times about 10 mg, at times about 20 mg, at times about 25 mg, at times about 35 mg, at times about 50 mg.In some embodiments, the method comprises administering the SMC directly to the lesion one or more times daily.

[0225] In some embodiments, the method comprises administering the SMC during a prodromal stage characterized by tingling, burning, or pain.

[0226] In some embodiments, the treatment inhibits progression to blister formation. In some embodiments, the treatment reduces lesion exudation.

[0227] In accordance with some aspects, the present disclosure provides use of at least one SMC represented by at least one of Formula (I), (II), (III), (V), (VI), (VII) in a manufacture of a composition.

[0228] In accordance with some aspects, the present disclosure provides use of at least one SMC represented by at least one of Formula (IVa), (IVb), (IVc), (IVd), (IVe) in a manufacture of a composition.

[0229] In accordance with some aspects, the present disclosure provides use of at least one SMC being ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X) in a manufacture of a composition.

[0230] The composition is in some examples a pharmaceutical composition.

[0231] It is to be understood that the terms "treat”, “treating”, “treatment" or forms thereof, as used herein, mean preventing, ameliorating or delaying the onset of one or more clinical indications of disease activity in a subject having a skin disease as described herein. Treatment refers to therapeutic treatment. Those in need of treatment are subjects suffering from a skin disease. Specifically, providing "preventive treatment" (to prevent) or a "prophylactic treatment" is acting in a protective manner, to defend against or prevent something, especially a condition or disease.

[0232] The term “treatment or prevention” as used herein, refers to the complete range of therapeutically positive effects of administrating to a subject including inhibition, reduction of, alleviation of, and relief from a skin disease related conditions. More specifically, treatment or prevention of recurrence of the disease, includes the prevention or postponement of development of the disease, prevention or postponement of development of symptoms and / or a reduction in the severity of such symptoms that willor are expected to develop. These further include ameliorating existing symptoms, preventing- additional symptoms and ameliorating or preventing the underlying metabolic causes of symptoms. It should be appreciated that the terms "inhibition", "moderation", “reduction”, "decrease" or "attenuation" as referred to herein, relate to the retardation, restraining or reduction of a process by any one of about 1% to 99.9%, specifically, about 1% to about 5%, about 5% to 10%, about 10% to 15%, about 15% to 20%, about 20% to 25%, about 25% to 30%, about 30% to 35%, about 35% to 40%, about 40% to 45%, about 45% to 50%, about 50% to 55%, about 55% to 60%, about 60% to 65%, about 65% to 70%, about 75% to 80%, about 80% to 85% about 85% to 90%, about 90% to 95%, about 95% to 99%, or about 99% to 99.9%, 100% or more.

[0233] With regards to the above, it is to be understood that, where provided, percentage values such as, for example, 10%, 50%, 120%, 500%, etc., are interchangeable with "fold change" values, i.e., 0.1, 0.5, 1.2, 5, etc., respectively.

[0234] The term "amelioration" as referred to herein, relates to a decrease in the symptoms, and improvement in a subject's condition brought about by the methods according to the present disclosure, wherein said improvement may be manifested in the forms of inhibition of processes associated with skin disease described herein, a significant reduction in their magnitude, or an improvement in a diseased subject physiological state.

[0235] The term "inhibit" and all variations of this term is intended to encompass the restriction or prohibition of progress and exacerbation of symptoms or a process progress.

[0236] The term "eliminate" relates to the substantial eradication or removal of the symptoms and possibly pathologic etiology, optionally, according to the methods of the present disclosure described herein.

[0237] The terms "delay", "delaying the onset", "retard" and all variations thereof are intended to encompass the slowing of the progress of skin disease.

[0238] As used herein, “disease”, “disorder”, “condition” and the like, as they relate to a subject's health, are used interchangeably and have meanings ascribed to each and all of such terms.

[0239] The present invention relates to the treatment of subjects, or patients, in need thereof. By “patient” or “subject in need” it is meant any organism who may be affected by the above-mentioned conditions, and to whom the treatment methods herein describedare desired, including humans, domestic and non-domestic mammals such as canine and feline subjects, bovine, simian, equine and murine subjects, rodents, domestic birds, aquaculture, fish and exotic aquarium fish. It should be appreciated that the treated subject may be also any reptile or zoo animal. More specifically, the methods and compositions of the invention are intended for mammals. By “mammalian subject” is meant any mammal for which the proposed therapy is desired, including human, equine, canine, and feline subjects, most specifically humans. It should be noted that specifically in cases of non-human subjects, the method of the invention may be performed using administration via injection, drinking water, feed, spraying, oral gavage and directly into the digestive tract of subjects in need thereof. It should be further noted that particularly in case of human subject, administering of the compositions of the invention to the patient includes both self-administration and administration to the patient by another person.

[0240] The invention provides methods for treating skin disease or related to skin disease. It is understood that the interchangeably used terms "associated" and "related", when referring to pathologies herein, mean diseases, disorders, conditions, or any pathologies which at least one of: share causalities, co-exist at a higher than coincidental frequency, or where at least one disease, disorder condition or pathology causes the second disease, disorder, condition or pathology.

[0241] The invention further provides the use of an effective amount of at least one SMC and any combination thereof in the preparation of a composition for treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject in need thereof.

[0242] It should be noted that the terms "disease", "disorder", "condition" and "illness", are equally used herein.

[0243] It should be appreciated that any of the methods described by the present disclosure may be applicable for treating and / or ameliorating any of the disorders disclosed herein or any condition associated therewith. It is understood that the interchangeably used terms "associated", “linked” and "related", when referring to pathologies herein, mean diseases, disorders, conditions, or any pathologies which at least one of: share causalities, co-exist at a higher than coincidental frequency, or where at least one disease, disorder condition or pathology causes the second disease, disorder, condition or pathology. More specifically, as used herein, “disease”, “disorder”, “condition”, “pathology” and the like,as they relate to a subject's health, are used interchangeably and have meanings ascribed to each and all of such terms. Specifically, "associated condition” may refer to a symptom, lesion or comorbidity that occurs together with a skin disease or in anatomical proximity thereto (e.g., pruritus, irritation, secondary eczematous reaction, acneiform rash).

[0244] The term “effective amount” relates to the amount of an active agent being at least one SMC present in a composition, that is needed to provide a desired level of active agent at the site of action in an individual to be treated to give an anticipated physiological response when such composition is administered. The precise amount will depend upon numerous factors, e.g., the active agent, the activity of the composition, the delivery device employed, the physical characteristics of the composition, intended patient use (i.e., the number of doses administered per day), patient considerations, and the like, and can readily be determined by one skilled in the art, based upon the information provided herein.

[0245] The term “alkyl” as used herein refers to a linear, branched saturated hydrocarbon having from 1 to 20 carbon atoms. The term “C1-C12 alkyl” or "C1-C12 alkylene" refers to a linear (straight), branched saturated hydrocarbon having from 1 to 20 carbon atoms, preferably 1 to 12 carbon atoms, in some embodiments, contain from 2 to 8 carbons, in yet some embodiments from 2 to 5 carbons, in yet some further embodiments, from 1 to 3 carbon atoms. It should be noted that alkyl refers to an alkyl end chain and alkylene refers to a middle chain alkyl. Representative C1-C12 alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, sec -butyl, iso-butyl, tertbutyl, cyclobutyl, pentyl, iso-pentyl, neo-pentyl, tert-pentyl, cyclopentyl, hexyl, cyclohexyl, heptyl, cycloheptyl, octyl, sec-octyl (1 -methylheptyl), and cyclooctyl. The alkyl can be substituted or unsubstituted. When substituted, the substituent can be as described herein.

[0246] The term “C1-C12 haloalkyl” as used herein refers to a C1-C12 alkyl as defined above, with one or more hydrogens substituted by halogen atoms.

[0247] The term “alkenyl” as used herein refers to a linear (straight), branched unsaturated hydrocarbon having from 2 to 20 carbon atoms and at least one carboncarbon double bond. The term “C2-C12 alkenyl” or "C2-C12 alkenylene" as used herein refers to a linear, branched unsaturated hydrocarbon having from 2 to 12 carbon atoms and at least onecarbon-carbon double bond, in some embodiments from 3 to 8 carbons, in yet some further embodiments, from 3 to 5 carbon atoms and at least one double bond. It should be noted that alkenyl refers to an alkyl end chain and alkenylene refers to a middle chain alkyl.

[0248] The term “C2-C12 haloalkenyl” as used herein refers to a C2-C12 alkenyl as defined above, with one or more hydrogens substituted by halogen atoms.

[0249] The term “alkynyl” as used herein refers to a linear, branched unsaturated hydrocarbon having from 2 to 20 carbon atoms and at least one carbon-carbon triple bond. The term “C2-C12 alkynyl” or "C2-C12 alkynylene" as used herein refers to a linear, branched unsaturated hydrocarbon having from 2 to 12 carbon atoms in certain embodiments, from 3 to 8 carbons, and at least one triple bond (at least one carboncarbon triple bond). It should be noted that alkynyl refers to an alkyl end chain and alkynylene refers to a middle chain alkyl.

[0250] The term “C2-C12 haloalkynyl” as used herein refers to a C2-C12 alkynyl as defined above, with one or more hydrogens substituted by halogen atoms.

[0251] As used herein “ alkoxy” refers to an alkyl group bonded to an oxygen atom.

[0252] Similarly, the term “C7-C72 alkoxyl” as used herein refers to a C1-C12 alkyl group linked to an oxygen. At times, the alkyl group may include one to twelve carbon atoms, at times between one to eight carbon atoms, at times one to five carbon atoms and at times one to three carbon atoms. Representative examples are methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, sec -butoxy, tert-butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like. In certain embodiments, the alkoxy is ethoxy.

[0253] The term “C7-C72 haloalkoxy” as used herein refers to a C1-C12 alkoxy as defined above, with one or more hydrogens substituted by halogen atoms.

[0254] The term “halogen” (halo or halide) refers to F, Cl, Br or I.

[0255] The term “cyano” describes a -C=N group.

[0256] The term “amino” as used herein encompass primary, secondary, tertiary or quaternary amines where the point of attachment is through the nitrogen atom which is substituted.

[0257] The term “amide” describes a -C(=O)-NR'R" group, where R' and R" are anysubstituent as defined herein (for example any one of “R” substitutions).

[0258] As used herein, “nitro” refers to -NO2.

[0259] The term “hydroxy” , as used herein, refers to an -OH group.

[0260] As used herein, “oxo” refers to =0.

[0261] As used herein, “urea” refers to -NRa-C(0)-NRa2 or -NRa-C(0)NRa-, wherein Ra is H or C1-C12 alkyl.

[0262] As used herein, “sulfonylurea” refers to -S(0)2-NRa-C(0)-NRa- or -NRa-C(0)-NRa-S02-, wherein Rais H or Ci-C 12 alkyl, e.g., an C1-C12 alkyl group as described herein.

[0263] As used herein, “ sulfonamidyl” refers to -S(0)2-NRa- or -NRa-S(0)2-, wherein Rais H or Ci-C 12 alkyl, e.g., an C1-C12 alkyl group as described herein.

[0264] As used herein, “cycloalkyl” refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and may be saturated, or partially unsaturated. Cycloalkyl groups include groups having from 3 to 12 ring atoms (i.e. C3-C10 cycloalkyl). Examples of cycloalkyl groups include, but are not limited to, groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl, and the like.

[0265] As used herein, “heterocycloalkyl” can be a stable 3- to 12-membered nonaromatic ring radical that comprises three to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. Examples of heterocycloalkyl groups include, but are not limited to, groups such as dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrrolidine, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, tetrahydropyrrole, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, and the like.

[0266] As used herein, “aryl” refers to a polyunsaturated, aromatic, hydrocarbon moiety which can be a single ring or multiple rings (e.g., 1 to 2 rings) which are fused together or linked covalently, having from six to twelve carbon atoms (i.e. C6-C12 aryl).Nonlimiting examples of aryl groups include phenyl, 1 -naphthyl, 2-naphthyl, and 4-biphenyl.

[0267] As used herein, the term “heteroaryl” refers to aryls as defined above where one or more carbons are substituted by heteroatoms. Exemplary heteroatoms include, but not limited to, nitrogen, sulfur, and oxygen. As used herein, "heteroaromatic" refers to refers to a monocyclic or multi-cyclic (fused) aromatic ring system, where one or more of the atoms in the ring system is a heteroatom, that is, an element other than carbon, including but not limited to, nitrogen, oxygen or sulfur. The term "heteroaromatic" used interchangeably with the term "heteroaryl" denotes a heterocyclic aromatic ring systems containing 5 to 12 atoms, with at least one, preferably two carbon atoms and one or more heteroatoms selected from nitrogen, oxygen and sulfur. Non-limiting examples include furan, thiophene, pyrrole, oxazole, oxadiazole, thiazole, imidazole, pyrazole, isoxazole, thiazolem benzofuran, indole, benzothiophene, benzoimidazole, indazole, benzoxazole, benzoisoxazole, benzothiazole, isobenzfuran, isoindole, purine, pyridine, pyrazine, pyrimidine, pyrisazine, quinoline, quinozaline, quinazoline, isoquinoline, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, [l,3,4]thiadiazole, thiadiazole, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzothiazolyl, benzoisothiazolyl, benzoxazolyl, benzisoxazolyl, purinyl, quinazolinyl, quinolizinyl, quinolinyl, isoquinolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl and the like.

[0268] Each one of the substitutions described herein may be optionally substituted by one or more substituents. The term “optionally substituted” refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated. The term substituted as used herein means that the compounds may contain one or more substituents, including, but not limited to, optionally substituted OH, halogen, C(=O), -COOH, -NH2, CN, alkyl, alkenyl, alkynyl, alkylene, straight alkenylene, alkynylene, haloalkyl, haloalkenyl, haloalkynyl, alkoxy, carboxyl, halogen, ring system including five to twelve atoms, aromatic or heteroaromatic ring, C(=O)-alkyl.It should be noted that the carbon number, as used herein, refers to the carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like.

[0269] The term "pharmaceutically acceptable salt" refers to salts derived from organic and inorganic acids of a compound described herein. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, hydrochloride, bromide, hydrobromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, ptoluenesulfonate, camphorsulfonate, napthalenesulfonate, propionate, succinate, fumarate, maleate, malonate, mandelate, malate, phthalate, and pamoate. The term “pharmaceutically acceptable salt” as used herein also refers to a salt of a compound described herein having an acidic functional group, such as a carboxylic acid functional group, and a base. Exemplary bases include, but are not limited to, hydroxide of alkali metals including sodium, potassium, calcium, magnesium and lithium; hydroxides of alkaline earth metals such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, organic amines such as un substituted or hydroxylsubstituted mono-, di-, or trialkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-(Cl-C6)-alkylamine), such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxy ethyl) amine; N-methyl-D-glucamine; morpholine; thiomorpholine; piperidine; pyrrolidine; and amino acids such as arginine, lysine, and the like. The term “pharmaceutically acceptable salt” also includes hydrates of a salt of a compound described herein.

[0270] The term “solvate” refers to an aggregate of a molecule with one or more solvent molecules, such as hydrate, alcoholate (aggregate or adduct with alcohol), and the like.

[0271] The term “hydrate” refers to a compound formed by the addition of water. The hydrates may be obtained by any known method in the art by dissolving the compounds in water and recrystallizing them to incorporate water into the crystalline structure.The term "stereoisomer” as used herein is meant to encompass an isomer that possess identical constitution as a corresponding stereoisomer, but which differs in the arrangement of its atoms in space from the corresponding stereoisomer.

[0272] The term "about" as used herein indicates values that may deviate up to 1%, more specifically 5%, more specifically 10%, more specifically 15%, and in some cases up to 20% higher or lower than the value referred to, the deviation range including integer values, and, if applicable, non-integer values as well, constituting a continuous range. Thus, as used herein the term "about" refers to ± 10 %.

[0273] It should be noted that various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range. Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging / ranges between" a first indicate number and a second indicate number and "ranging / ranges from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals there between.

[0274] As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

[0275] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separatelyor in any suitable sub combination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

[0276] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

[0277] Disclosed and described, it is to be understood that this invention is not limited to the particular examples, methods steps, and compositions disclosed herein as such methods steps and compositions may vary somewhat. It is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only and not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.

[0278] It must be noted that, as used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise.

[0279] NON-LIMITING EXAMPLES

[0280] Example 1 - Topical Administration of Metamizole Sodium for Treating Herpes Labialis

[0281] A 39-year-old female reported a tingling sensation, characteristic of the onset of herpes labialis, on the lip. A single drop of liquid metamizole sodium (Optalgin) was applied topically at the site of tingling. The patient experienced immediate relief and no further development of the lesion.

[0282] Upon repeated applications at the onset of similar symptoms, the formation of visible sores was consistently prevented. In cases where the lesion had already erupted, topical administration of metamizole sodium caused a stronger tingling sensation but led to cessation of progression within 1-2 days, with the lesion remaining dry and nonexudative. After approximately 10 such episodes treated in this manner, the herpes episodes ceased entirely and did not recur for several years.Example 2 - Relief of Herpes and Acne-like Rash

[0283] A 39-year-old female with recurrent herpes and mild skin eruptions (acne-like rash) received topical administration of liquid metamizole sodium. Herpes symptoms improved within 12-24 hours, and episodes ceased completely after approximately two years. Application to rash sites resulted in drying of the lesions and relief of irritation.

[0284] Example 3 - Chronic Ear Canal Itch and Herpes Lesions

[0285] A 49-year-old female with chronic pruritus in the ear canal (lasting over 35 years) and herpes labialis was treated with topical administration of liquid metamizole sodium. The solution was applied directly to the lips and to the entrance of the external auditory canal using a cotton swab. Herpes symptoms improved within hours. For ear canal itching, metamizole sodium provided immediate relief and prolonged symptom-free periods of 10-14 days. In addition, topical application to eczema on the foot reduced itching effectively.

[0286] Example 4 - Immediate Relief in Herpes Episodes

[0287] A 35-year-old male received topical administration of liquid metamizole sodium at the onset of herpes symptoms and during the active lesion stage. In both cases, the patient reported immediate symptom relief.

[0288] Example 5 - Improvement of Open Herpes Lesions

[0289] A 53 -year-old female received topical administration of liquid metamizole sodium to an active herpes lesion. Symptom improvement was reported within hours, with the lesion drying out and exudation ceasing.

[0290] Example 6 - Rapid Symptom Resolution in Adolescent Herpes

[0291] A 17-year-old female with an open herpes sore received topical administration of liquid metamizole sodium and reported significant improvement within hours.

[0292] Example 7 - Soothing of Large Open Herpes Sores

[0293] A 24-year-old male presented with large, open herpes lesions and received topical administration of liquid metamizole sodium. This resulted in immediate soothing and cessation of fluid discharge within hours.

[0294] Example 8 - Pediatric Use Following Pustular Herpes OutbreakA 12-year-old girl developed herpes lesions containing pus. Liquid metamizole sodium was topically administered following the outbreak. Symptoms and pain subsided within one day, and the treatment was described as acting “like magic.”

Claims

CLAIMS:

1. A small molecule compound (SMC) for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease, wherein said SMC has the general Formula (I):‘2N N(I)or a pharmaceutically acceptable salt, solvate, hydrate, any stereoisomer thereof or a physiologically functional derivative thereof,wherein each of Ri, R2, R3, R4, and R5, is independently hydrogen, cyano, amino, amide, nitro, hydroxy, oxo, halo, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl, C2-C12 haloalkenyl, C2-Ci2alkynyl, C2-C12 haloalkynyl, C1-C12 alkoxy, C1-C12 haloalkoxy, urea, sulfonylurea, sulfonamidyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, trifluoromethyl, -N(R6)(R7), C(=O), -C(=O)R6, -CH2R6, -CO2R6, -C(O)N(R6)(R7), -SO2N(R6)(R7), -SOR6, -SO2(R6), or Li- R8, each optionally substituted with C1-C12 alkyl, C1-C12 haloalkyl, or halo;Li is -(CH2)m-,-C(O)-, -O-, -NH-, -O-CH2-, -N-(CH2)m-, -NH-C(O)- , m is selected from 0, 1, 2, 3, 4, 5 or 6,R8is hydrogen, cyano, amino, amide, nitro, hydroxy, oxo, halo, C1-C12 alkyl, Ci-C12 haloalkyl, C2-C12 alkenyl, C2-C12 haloalkenyl, C2-C12 alkynyl, C2-C12 haloalkynyl, Ci-C 12 alkoxy, C1-C12 haloalkoxy, urea, sulfonylurea, sulfonamidyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, trifluoromethyl, -N(Rn)(R12), -C(O)Rn, -CH2R11, -CO2R6, -C(O)N(R6)(R7), -SO2N(R6)(R7), -SO2(R6),each R6and R7is independently H, hydroxyl, C1-C12 alkyl, C1-C12 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl.

2. The SMC for use of claim 1, wherein said SMC has the general Formula (II):(II).The SMC for use of claim 1 or 2, wherein said SMC has the general Formula (VII):(VII).

4. The SMC for use of any one of claims 1 to 3, wherein R2 is hydrogen or C1-C12 alkyl, R3 is hydrogen or C1-C12 alkyl, R5 is hydrogen, C1-C12 alkyl.

5. The SMC for use of any one of claims 1 to 4, wherein R2 is Ci alkyl, R3 is Ci alkyl, R5 is Ci alkyl.

6. The SMC for use of any one of claims 1 to 5, wherein said SMC having the chemical structure of Formula (X):((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid.

7. The SMC for use of any one of claims 1 to 6, wherein said SMC is in the form of a pharmaceutically acceptable salt selected from the group consisting of a sodium salt, a calcium salt, a potassium salt, a magnesium salt, and any combination thereof.

8. The SMC for use of any one of claims 1 to 7, wherein said SMC is sodium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonate.

9. The SMC for use of any one of claims 1 to 7, wherein said SMC is magnesium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)methylamino]methanesulfonate.

10. The SMC for use of any one of claims 1 to 7, wherein said SMC is calcium;[(l,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonate.

11. The SMC for use of any one of claims 1 to 10, wherein said skin disease is a skin infection disease, an inflammatory skin disease, an autoimmune skin disease or any combination thereof.

12. The SMC for use of any one of claims 1 to 10, wherein said skin disease is a skin infection disease.

13. The SMC for use of claim 12, wherein said skin infection disease is one or more of a viral infection, a bacterial infection, a fungal infection, a parasitic infection or any combination thereof.

14. The SMC for use of claim 12, wherein said skin infection disease is a viral infection.

15. The SMC for use of claim 13 or 14, wherein said viral infection is caused by a herpes virus.

16. The SMC for use of claim 15, wherein said herpes virus is herpes simplex or varicella-zoster (VZV).

17. The SMC for use of claim 16, wherein said herpes simplex is HSV-1.

18. The SMC for use of claim 13 or 14, wherein said viral infection is herpes labialis.

19. The SMC for use of claim 11, wherein said inflammatory skin disease is one or more of dermatitis, eczema (atopic dermatitis), seborrheic dermatitis, psoriasis.

20. A SMC having the chemical structure of Formula (X):((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid or a pharmaceutically acceptable salt, solvate, hydrate, any stereoisomer thereof or a physiologically functional derivative thereof for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease.

21. An SMC having the chemical structure of Formula (X) or a sodium salt thereof for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease.

22. The SMC for use of claim 20 or 21, wherein said skin disease is a skin infection disease, an inflammatory skin disease, an autoimmune skin disease or any combination thereof.

23. The SMC for use of claim 22, wherein said skin infection disease is one or more of a viral infection, a bacterial infection, a fungal infection, a parasitic infection or any combination thereof.

24. The SMC for use of any one of claim 22 or 23, wherein said skin infection disease is a viral infection.

25. The SMC for use of claim 24, wherein said viral infection is caused by a herpes virus.

26. The SMC for use of claim 25, wherein said herpes virus is herpes simplex or varicella-zoster (VZV).

27. The SMC for use of claim 22, wherein said inflammatory skin disease is one or more of dermatitis, eczema (atopic dermatitis), seborrheic dermatitis, psoriasis.

28. A SMC having the chemical structure of Formula (X):(X) ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid or a pharmaceutically acceptable salt, solvate, hydrate, any stereoisomer thereof or a physiologically functional derivative thereof for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of herpes labialis.

29. The SMC for use of claim 28, wherein the pharmaceutically acceptable salt is sodium.

30. The SMC for use of claim 28 or 29, wherein the SMC is administered topically to a herpes lesion or to a prodromal site of lesion formation.

31. A pharmaceutical composition comprising at least one SMC according to any one of claims 1 to 30.

32. The pharmaceutical composition of claim 31, wherein said pharmaceutical composition is formulated for topical administration.

33. The pharmaceutical composition of claim 31 or 32, wherein said pharmaceutical composition is formulated as a cream, a gel, an ointment, a lotion, a paste, a spray, an aerosol, transdermal patch, foam, solution, suspension, powder, film, film forming solution or any combination thereof.

34. A method for treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a skin disease in a subject in need thereof, said method comprises administering to said subject a therapeutically effective amount of at least one SMC of any one of claims 1 to 30, any vehicle, matrix, nano- or micro-particle or any composition comprising the same.

35. The method according to claim 34, wherein said subject is a subject suffering from a skin disease.

36. The method according to claim 34 or 35, comprising topical administration to said subject said SMC being ((l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-lH-pyrazol-4-yl)(methyl)amino)methanesulfonic acid having the chemical structure of Formula (X) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or physiologically functional derivative thereof.

37. The method of any one of claims 34 to 36, wherein said skin disease is a skin infection disease, an inflammatory skin disease, an autoimmune skin disease or any combination thereof.

38. The method of claim 37, wherein said skin infection disease is one or more of a viral infection, a bacterial infection, a fungal infection, a parasitic infection or any combination thereof.

39. The method of claim 38, wherein said viral infection is caused by a herpes virus.

40. The method of claim 39, wherein said herpes virus is herpes simplex or varicellazoster (VZV).

41. The method of claim 37, wherein said inflammatory skin disease is one or more of dermatitis, eczema (atopic dermatitis), contact dermatitis, seborrheic dermatitis, psoriasis.

42. A method for treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of herpes labialis in a subject in need thereof, comprising topically administering to a herpes lesion or prodromal lesion site an effective amount of a SMC of any one of claims 1 to 30, any vehicle, matrix, nano- or micro-particle or any composition comprising the same.

43. The method of claim 42, comprising administering the SMC directly to the lesion one or more times daily.

44. The method of claim 42, comprising administering the SMC during a prodromal stage characterized by tingling, burning, or pain.

45. The method of claim 42, wherein the treatment inhibits progression to blister formation.

46. The method of claim 42, wherein the treatment reduces lesion exudation.